CannPal Animal Therapeutics Limited (ASX:CP1) has achieved a milestone in entering into a manufacturing agreement with New Zealand based veterinary contract manufacturing organisation, Jaychem Industries Ltd.
The agreement will allow CannPal to proceed with developing DermaCann, a high-quality cannabinoid derived therapeutic that is targeted to meet GMP (Good Manufacturing Processes) standards.
The company has now commissioned pharmaceutical quality assurance and GMP compliance consultants, Seer Pharma, to perform a GMP Inspection of Jaychem to relevant standards that will apply to Dermacann in the company’s target regions.
CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.
The core strategy is to use compounds derived from cannabis that have been de-risked in clinical humans studies, to progress straight into animal clinical trials.